Literature DB >> 11453524

Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.

A Bossowski1, M Urban.   

Abstract

It has been shown that human thyrocytes can synthesize cytokines which activate T and B lymphocytes. These immune cells play important roles in the initiation and continuation of thyroid autoimmunity. The aim of this study was to estimate serum concentrations of soluble interleukin-6 receptor (sIL-6R), interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients with Graves' disease (GD) (n=44, mean age 14.8 years), in patients with nontoxic nodular goiter (NTNG) (n=36, mean age 15.6 years) and in a group of healthy controls (n=20, mean age 14.5 years). ELISA was used to determine the concentration of cytokines, antithyroglobulin and antithyroid peroxidase antibodies in patients with thyroid disease. Radio receptor assay (RRA) was performed to detect anti-TSH receptor autoantibodies (TRAb). Serum levels of IL-6, sIL-6R and IL-8 were markedly elevated in patients with GD before treatment with methimazole (p<0.0001 for IL-6, p<0.006 for sIL-6R, p<0.004 for IL-8) and after 8 weeks of therapy (p<0.011 for IL-6, p<0.04 for IL-8). However, following 24 months of treatment, normal serum concentrations of these cytokines were restored. Furthermore, patients with NTNG showed a slightly elevated concentration of cytokines (IL-6, IL-8). Serum levels of tri-iodothyronine in patients with GD positively correlated with serum concentrations of IL-6 (r = 0.35, p<0.025) and sIL-6R (r = 0.31, p<0.047), while no correlation was found between thyroxine and cytokines. Moreover, we observed a positive correlation between serum levels of TPO-Abs, TRAb and IL-6 (r = 0.43, p<0.008; r = 0.5, p<0.003) and between TPO-Abs and IL-8 (r = 0.67, p<0.0001). However, in patients with NTNG no correlation was observed between serum levels of antithyroid antibodies or thyroid hormones and serum levels of cytokines. We conclude that the cytokines (IL-6, sIL-6R, IL-8) could play an important role in the development of Graves' disease and that their levels are modulated by thyreostatic treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453524     DOI: 10.1515/jpem.2001.14.6.741

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  10 in total

1.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

2.  Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).

Authors:  Raymond S Douglas; Tünde Mester; Anna Ginter; Denise S Kim
Journal:  Trans Am Ophthalmol Soc       Date:  2014

3.  The Effect of Inflammation on the Formation of Thyroid Nodules.

Authors:  Zexin Li; Yiteng Huang; Xiang Chen; Chiju Wei; Peixuan Yang; Wencan Xu
Journal:  Int J Endocrinol       Date:  2020-07-10       Impact factor: 3.257

4.  Association studies of interleukin-8 gene in Graves' disease and Graves' ophthalmopathy.

Authors:  Li-qun Gu; Hui-ying Jia; Yong-ju Zhao; Nan Liu; Shu Wang; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2009-10-09       Impact factor: 3.633

5.  Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.

Authors:  Hong Chen; Tünde Mester; Nupur Raychaudhuri; Courtney Y Kauh; Shivani Gupta; Terry J Smith; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2014-05-30       Impact factor: 5.958

6.  Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases.

Authors:  Toral P Kobawala; Girish H Patel; Dhara R Gajjar; Kamini N Patel; Premal B Thakor; Urvi B Parekh; Kirti M Patel; Shilin N Shukla; Pankaj M Shah
Journal:  J Thyroid Res       Date:  2011-03-08

7.  The effects of royal jelly on autoimmunity in Graves' disease.

Authors:  Cihangir Erem; Orhan Deger; Ercüment Ovali; Yasam Barlak
Journal:  Endocrine       Date:  2006-10       Impact factor: 3.925

8.  The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overt hyperthyroidism.

Authors:  Anna Popławska-Kita; Katarzyna Siewko; Beata Telejko; Anna Modzelewska; Janusz Myśliwiec; Robert Milewski; Maria Górska; Małgorzata Szelachowska
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

9.  Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells.

Authors:  Yanqun Li; Zi Wang; Ting Yu; Bingni Chen; Jinshun Zhang; Kunzhao Huang; Zhong Huang
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Effects of vitamin D on thyroid autoimmunity markers in Hashimoto's thyroiditis: systematic review and meta-analysis.

Authors:  Jingwen Zhang; Yuting Chen; Hongyan Li; Hong Li
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.